bioMérieux, Marcy l’Etoile, France, which specializes in the field of in vitro diagnostics, has received FDA 510(k) clearance to market Vidas® NT-proBNP (N-terminal pro-B-type natriuretic peptide), a test that helps diagnose heart failure.
The test is a quantitative marker of heart stress with the potential to detect all stages of heart failure—even the early stages—which can be difficult to detect. It provides objective diagnostic information that helps clinicians distinguish heart failure from other disease states with similar clinical symptoms, such as lung diseases or pulmonary embolism.
NT-proBNP can be used to assess the prognosis of patients with established heart failure or acute coronary syndrome.
The Vidas® emergency panel available in the United States includes markers of cardiac necrosis, venous thromboembolism, and bacterial infections. More than 24,000 systems are installed worldwide.
